EPA:SAN

Sanofi News Headlines

€82.73
+0.50 (+0.61 %)
(As of 09/22/2021 12:00 AM ET)
Add
Compare
Today's Range
€81.82
€82.99
50-Day Range
€81.35
€90.73
52-Week Range
€63.09
€92.97
Volume1.70 million shs
Average Volume3.05 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week

Sanofi Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SAN
News Sentiment

-0.08

0.37

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SAN Articles
This Week

4

3

SAN Articles
Average Week

Get Sanofi News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Sanofi (EPA SAN) News Headlines Today

SourceHeadline
Sanofi (EPA:SAN) PT Set at €80.00 by Deutsche Bank AktiengesellschaftSanofi (EPA:SAN) PT Set at €80.00 by Deutsche Bank Aktiengesellschaft
americanbankingnews.com - September 23 at 11:02 AM
Sanofi (EPA:SAN) Given Consensus Rating of "Buy" by AnalystsSanofi (EPA:SAN) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - September 21 at 1:36 AM
Sanofi (EPA:SAN) Stock Price Passes Below 200 Day Moving Average of $85.81Sanofi (EPA:SAN) Stock Price Passes Below 200 Day Moving Average of $85.81
americanbankingnews.com - September 18 at 2:18 AM
Merger Arbitrage Mondays - Sanofis Second Purchase In 6 Weeks - Seeking AlphaMerger Arbitrage Mondays - Sanofi's Second Purchase In 6 Weeks - Seeking Alpha
seekingalpha.com - September 13 at 8:54 AM
Sanofi autoimmune skin candidate rilzabrutinib fails in phase 3 - Seeking AlphaSanofi autoimmune skin candidate rilzabrutinib fails in phase 3 - Seeking Alpha
seekingalpha.com - September 10 at 9:21 AM
UBS Group Analysts Give Sanofi (EPA:SAN) a €100.00 Price TargetUBS Group Analysts Give Sanofi (EPA:SAN) a €100.00 Price Target
americanbankingnews.com - September 9 at 10:08 AM
(KDMN): Johnson Fistel Investigates Proposed Sale of Kadmon Holdings; Is $9.50 a Fair Price?(KDMN): Johnson Fistel Investigates Proposed Sale of Kadmon Holdings; Is $9.50 a Fair Price?
finance.yahoo.com - September 9 at 8:23 AM
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus - GlobeNewswireSanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus - GlobeNewswire
globenewswire.com - September 9 at 3:23 AM
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigusSanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
finance.yahoo.com - September 9 at 3:23 AM
ADRs End Lower; Nio, Sanofi Among Companies Actively Trading - MarketWatchADRs End Lower; Nio, Sanofi Among Companies Actively Trading - MarketWatch
marketwatch.com - September 8 at 9:28 PM
Sanofi (EPA:SAN) Given a €90.00 Price Target by Barclays AnalystsSanofi (EPA:SAN) Given a €90.00 Price Target by Barclays Analysts
americanbankingnews.com - September 8 at 1:00 PM
Sanofi (EPA:SAN) Given a €120.00 Price Target at Jefferies Financial GroupSanofi (EPA:SAN) Given a €120.00 Price Target at Jefferies Financial Group
americanbankingnews.com - September 8 at 6:18 AM
Sanofi (EPA:SAN) Given a €120.00 Price Target by Jefferies Financial Group AnalystsSanofi (EPA:SAN) Given a €120.00 Price Target by Jefferies Financial Group Analysts
americanbankingnews.com - September 2 at 1:02 PM
Deutsche Bank Aktiengesellschaft Analysts Give Sanofi (EPA:SAN) a €80.00 Price TargetDeutsche Bank Aktiengesellschaft Analysts Give Sanofi (EPA:SAN) a €80.00 Price Target
americanbankingnews.com - September 1 at 9:05 AM
Sanofi (SNY)/Regenerons Dupixent Meets Eczema Study Goal - NasdaqSanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal - Nasdaq
nasdaq.com - August 30 at 1:51 PM
Sanofi (SNY)/Regenerons Dupixent Meets Eczema Study GoalSanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal
finance.yahoo.com - August 30 at 1:51 PM
Regeneron, Sanofi: Dupixent Hits Endpoints in Atopic Dermatitis Under Age 6 - MarketWatchRegeneron, Sanofi: Dupixent Hits Endpoints in Atopic Dermatitis Under Age 6 - MarketWatch
marketwatch.com - August 30 at 6:50 AM
Regeneron, Sanofis Dupixent meets all endpoints in late-stage atopic dermatitis study - Seeking AlphaRegeneron, Sanofi's Dupixent meets all endpoints in late-stage atopic dermatitis study - Seeking Alpha
seekingalpha.com - August 30 at 1:49 AM
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 monthsDupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
finance.yahoo.com - August 30 at 1:49 AM
House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On Unacceptably High Insulin Prices - Yahoo FinanceHouse Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices - Yahoo Finance
finance.yahoo.com - August 20 at 10:22 PM
Pharma Stock Roundup: FDA Nod for SNYs Pompe Drug & New Use of MRKs KeytrudaPharma Stock Roundup: FDA Nod for SNY's Pompe Drug & New Use of MRK's Keytruda
finance.yahoo.com - August 13 at 11:45 AM
Sanofi Genzyme wins FDA approval of Pompe treatment Nexviazyme - Seeking AlphaSanofi Genzyme wins FDA approval of Pompe treatment Nexviazyme - Seeking Alpha
seekingalpha.com - August 6 at 11:40 AM
U.S. FDA approves Sanofis Pompe disease treatment - ReutersU.S. FDA approves Sanofi's Pompe disease treatment - Reuters
reuters.com - August 6 at 11:40 AM
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNYs TBIO Buyout, FDA UpdatesPharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates
finance.yahoo.com - August 6 at 11:40 AM
UPDATE 1-U.S. FDA approves Sanofis Pompe disease treatmentUPDATE 1-U.S. FDA approves Sanofi's Pompe disease treatment
finance.yahoo.com - August 6 at 11:40 AM
Analysis: Sanofis COVID-19 vaccine setback, drug pipeline cast long shadow - ReutersAnalysis: Sanofi's COVID-19 vaccine setback, drug pipeline cast long shadow - Reuters
reuters.com - August 5 at 5:39 PM
Regeneron, Sanofi: Libtayo Phase 3 Study Meets Primary Endpoint - MarketWatchRegeneron, Sanofi: Libtayo Phase 3 Study Meets Primary Endpoint - MarketWatch
marketwatch.com - August 5 at 12:39 PM
Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts PerformanceRegeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance
finance.yahoo.com - August 5 at 12:39 PM
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancerPhase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
finance.yahoo.com - August 5 at 7:38 AM
Sanofi confirms $3.2 bln offer to buy U.S. biotech firm Translate Bio - ReutersSanofi confirms $3.2 bln offer to buy U.S. biotech firm Translate Bio - Reuters
reuters.com - August 3 at 11:21 PM
UPDATE 2--Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 bln deal - ReutersUPDATE 2--Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 bln deal - Reuters
reuters.com - August 3 at 11:21 PM
PepsiCo, Translate Bio, Sanofi, Eli Lilly – On TheStreet Tuesday - TheStreetPepsiCo, Translate Bio, Sanofi, Eli Lilly – On TheStreet Tuesday - TheStreet
thestreet.com - August 3 at 6:21 PM
Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights - BenzingaSanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights - Benzinga
benzinga.com - August 3 at 6:21 PM
Viatris gets FDA approval of first biosimilar version of Sanofis insulin Lantus - MarketWatchViatris gets FDA approval of first biosimilar version of Sanofi's insulin Lantus - MarketWatch
marketwatch.com - July 29 at 8:43 AM
Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI - Yahoo FinanceSanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI - Yahoo Finance
finance.yahoo.com - July 29 at 8:43 AM
Sanofis Pompe Disease Enzyme Replacement Therapy Gets EMAs CHMP Backing - Yahoo FinanceSanofi's Pompe Disease Enzyme Replacement Therapy Gets EMA's CHMP Backing - Yahoo Finance
finance.yahoo.com - July 27 at 6:40 PM
Global Interleukin Inhibitors Market (2020 to 2026) - Featuring AbbVie, AstraZeneca and Sanofi Among Others - ResearchAndMarkets.com - Yahoo FinanceGlobal Interleukin Inhibitors Market (2020 to 2026) - Featuring AbbVie, AstraZeneca and Sanofi Among Others - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - July 23 at 10:01 AM
‘It’s very premature to talk about booster vaccines’: Doctor‘It’s very premature to talk about booster vaccines’: Doctor
finance.yahoo.com - July 21 at 2:24 PM
EU Drug Agency Begins Rolling Review of Sanofi Covid-19 Vaccine Candidate - MarketWatchEU Drug Agency Begins Rolling Review of Sanofi Covid-19 Vaccine Candidate - MarketWatch
marketwatch.com - July 20 at 12:15 PM
BRIEF-Sanofi: rolling reviews of COVID-19 recombinant vaccine to start soon in UK, Canada and Singapore - ReutersBRIEF-Sanofi: rolling reviews of COVID-19 recombinant vaccine to start soon in UK, Canada and Singapore - Reuters
reuters.com - July 20 at 12:15 PM
Sanofis Reorganization Needs To Be Faster - Seeking AlphaSanofi's Reorganization Needs To Be Faster - Seeking Alpha
seekingalpha.com - July 19 at 6:13 AM
Sanofi cant escape second bellwether trial over Taxotere - ReutersSanofi can't escape second bellwether trial over Taxotere - Reuters
reuters.com - July 15 at 7:38 PM
Sanofi to divest eight consumer brands in Latin America - Seeking AlphaSanofi to divest eight consumer brands in Latin America - Seeking Alpha
seekingalpha.com - July 13 at 12:32 PM
Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris - Yahoo FinanceSanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris - Yahoo Finance
finance.yahoo.com - July 13 at 1:46 AM
Sanofi Bets Over $1B For Eurekas Multiple Myeloma CandidateSanofi Bets Over $1B For Eureka's Multiple Myeloma Candidate
finance.yahoo.com - July 6 at 6:59 PM
Sanofi to ready its COVID-19 vaccine by December - Seeking AlphaSanofi to ready its COVID-19 vaccine by December - Seeking Alpha
seekingalpha.com - July 6 at 1:58 PM
Walmart Is Selling Its Own Insulin. What That Means for 3 Drug Makers. - BarronsWalmart Is Selling Its Own Insulin. What That Means for 3 Drug Makers. - Barron's
barrons.com - June 29 at 6:04 PM
Sanofi Divests 16 Consumer Health Brands To Stada - BenzingaSanofi Divests 16 Consumer Health Brands To Stada - Benzinga
benzinga.com - June 28 at 2:46 PM
Sanofi sells portfolio of regional consumer brands to Stada - Yahoo FinanceSanofi sells portfolio of regional consumer brands to Stada - Yahoo Finance
finance.yahoo.com - June 28 at 9:46 AM
EMA to update Regeneron/Sanofis Dupixent SmPC for adults with atopic dermatitis - Seeking AlphaEMA to update Regeneron/Sanofi's Dupixent SmPC for adults with atopic dermatitis - Seeking Alpha
seekingalpha.com - June 28 at 4:45 AM
Get Sanofi News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.